JP2018536710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536710A5 JP2018536710A5 JP2018543283A JP2018543283A JP2018536710A5 JP 2018536710 A5 JP2018536710 A5 JP 2018536710A5 JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018536710 A5 JP2018536710 A5 JP 2018536710A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- daily dose
- statin
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 claims 5
- 229950004781 gemcabene Drugs 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 5
- 102000004146 ATP citrate synthases Human genes 0.000 claims 4
- 108090000662 ATP citrate synthases Proteins 0.000 claims 4
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 4
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 4
- 108010018763 Biotin carboxylase Proteins 0.000 claims 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims 4
- 230000000087 stabilizing effect Effects 0.000 claims 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 229960003765 fluvastatin Drugs 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 229960004844 lovastatin Drugs 0.000 claims 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 3
- 229960002797 pitavastatin Drugs 0.000 claims 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 3
- 229960002965 pravastatin Drugs 0.000 claims 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 3
- 229960000672 rosuvastatin Drugs 0.000 claims 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 3
- 229960002855 simvastatin Drugs 0.000 claims 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010045263 Type IIb hyperlipidaemia Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- 230000002440 hepatic effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 101150102415 Apob gene Proteins 0.000 claims 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 1
- 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- -1 cholesteryl ester Chemical class 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252147P | 2015-11-06 | 2015-11-06 | |
| US201562252195P | 2015-11-06 | 2015-11-06 | |
| US62/252,195 | 2015-11-06 | ||
| US62/252,147 | 2015-11-06 | ||
| PCT/US2016/060837 WO2017079748A1 (en) | 2015-11-06 | 2016-11-07 | Treatment of mixed dyslipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536710A JP2018536710A (ja) | 2018-12-13 |
| JP2018536710A5 true JP2018536710A5 (enExample) | 2019-12-19 |
Family
ID=58663111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543283A Pending JP2018536710A (ja) | 2015-11-06 | 2016-11-07 | 混合型脂質異常症の治療 |
| JP2018543079A Pending JP2018532808A (ja) | 2015-11-06 | 2016-11-07 | 心血管疾患の処置のためのゲムカベンの組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543079A Pending JP2018532808A (ja) | 2015-11-06 | 2016-11-07 | 心血管疾患の処置のためのゲムカベンの組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9849104B2 (enExample) |
| EP (2) | EP3370703A4 (enExample) |
| JP (2) | JP2018536710A (enExample) |
| KR (2) | KR20180073597A (enExample) |
| CN (2) | CN108366957A (enExample) |
| AU (2) | AU2016349634A1 (enExample) |
| BR (2) | BR112018007857A2 (enExample) |
| CA (2) | CA3001627A1 (enExample) |
| HK (2) | HK1257929A1 (enExample) |
| IL (2) | IL258819A (enExample) |
| MA (1) | MA43190A (enExample) |
| MX (2) | MX2018005096A (enExample) |
| PH (1) | PH12018500972A1 (enExample) |
| RU (2) | RU2018120599A (enExample) |
| SG (2) | SG10201912754UA (enExample) |
| WO (2) | WO2017079748A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| ES2860423T3 (es) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| EP3218349A2 (en) | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| MX2018005096A (es) * | 2015-11-06 | 2018-08-15 | Gemphire Therapeutics Inc | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. |
| CN109415685B (zh) | 2016-05-05 | 2023-07-04 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| KR102399254B1 (ko) | 2016-09-28 | 2022-05-17 | 아이거 바이오파마슈티컬스 인코포레이티드 | 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물 |
| SG10202104575WA (en) | 2016-11-04 | 2021-06-29 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| CA3045145A1 (en) | 2016-12-05 | 2018-06-14 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
| US12281334B2 (en) | 2017-04-14 | 2025-04-22 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| WO2018193427A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
| WO2019074793A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME |
| CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| JP2021504479A (ja) * | 2017-11-28 | 2021-02-15 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 非アルコール性脂肪性肝炎の処置のための方法および医薬組成物 |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| CN112823012A (zh) | 2018-09-12 | 2021-05-18 | 儿童医院医学中心 | 用于产生造血干细胞及其衍生物的类器官组合物 |
| BR112021005086A2 (pt) | 2018-09-18 | 2021-06-08 | 1Globe Biomedical Co., Ltd. | tratamento para doença hepática gordurosa não alcoólica |
| EP3863643A4 (en) * | 2018-10-12 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions |
| JP2022505033A (ja) * | 2018-10-18 | 2022-01-14 | ジェムフィアー セラピューティクス インコーポレイテッド | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| WO2020160371A1 (en) | 2019-02-01 | 2020-08-06 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| US12534709B2 (en) | 2019-05-31 | 2026-01-27 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| CA3141807A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| CN112851660B (zh) * | 2019-11-12 | 2022-03-18 | 广东药科大学 | 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途 |
| CN114957119B (zh) * | 2022-05-05 | 2023-06-16 | 武汉大学中南医院 | 一种四氢喹啉螺1,3-茚二酮类衍生物及其制备方法与应用 |
| WO2025186785A1 (en) * | 2024-03-08 | 2025-09-12 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Oral pharmaceutical composition of pitavastatin, method and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT381664B (de) | 1984-02-07 | 1986-11-10 | Steyr Daimler Puch Ag | Einrichtung zur ueberwachung elektrischer, von einer gesteuerten wechselstromquelle gespeister widerstandsschweissvorgaenge, insbesondere punktschweissungen |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| CA2039763A1 (en) | 1990-04-30 | 1991-10-31 | Henry Y. Pan | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| NZ286920A (en) | 1995-07-03 | 1997-06-24 | Sankyo Co | Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma |
| WO1997016187A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine antagonists |
| WO1997016181A1 (en) | 1995-11-03 | 1997-05-09 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
| EP1017390B1 (en) * | 1997-07-31 | 2007-04-18 | Kos Life Sciences, Inc. | Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form |
| NZ503982A (en) | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US20030105154A1 (en) * | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| CA2480634A1 (en) * | 2002-03-29 | 2003-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| WO2004045596A1 (en) * | 2002-11-15 | 2004-06-03 | Warner-Lambert Company Llc | Method of lowering crp and reducing systemic inflammation |
| US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
| JP2006131559A (ja) * | 2004-11-05 | 2006-05-25 | Takeda Chem Ind Ltd | 含窒素複素環化合物 |
| WO2006054308A2 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| MX2007011031A (es) * | 2005-03-08 | 2008-04-21 | Reliant Pharmaceuticals Inc | Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos. |
| US20090186834A1 (en) * | 2005-03-24 | 2009-07-23 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
| US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| CA2634940A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| CN104825397A (zh) * | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
| CN101522623B (zh) | 2006-08-03 | 2013-06-12 | 塔夫茨大学信托人 | 无潮红烟酸类似物和其使用方法 |
| WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| FI20080353A0 (fi) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| WO2008124505A2 (en) * | 2007-04-05 | 2008-10-16 | Ironwood Pharmaceuticals,Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US9307371B2 (en) | 2008-01-18 | 2016-04-05 | Verizon Patent And Licensing Inc. | Method and system for SMS/MMS messaging to a connected device |
| RU2010151944A (ru) * | 2008-05-20 | 2012-06-27 | Серенис Терапьютикс С.А. (Fr) | Ниацин и нспвс для комбинированной терапии |
| US20110082119A1 (en) * | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| US20120202849A1 (en) | 2009-10-12 | 2012-08-09 | Anil Pareek | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
| WO2011085271A2 (en) * | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| AU2011270719B2 (en) * | 2010-06-24 | 2015-09-24 | Arisaph Pharmaceuticals, Inc. | Niacin mimetics, and methods of use thereof |
| TR201005325A2 (tr) * | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
| ES2608177T3 (es) * | 2010-12-27 | 2017-04-06 | Gemphire Therapeutics Inc. | Gemcabeno y derivados para el tratamiento de la pancreatitis |
| EP2604256B1 (en) * | 2011-12-14 | 2016-04-13 | Hexal AG | Multi layer coatings |
| CN102525942A (zh) * | 2012-01-05 | 2012-07-04 | 金陵药业股份有限公司 | 一种阿托伐他汀钙肠溶微丸及其制备方法 |
| JP6295205B2 (ja) * | 2012-01-06 | 2018-03-14 | ジェムファイア セラピューティクス インクＧｅｍｐｈｉｒｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 心血管疾患のリスクを低減する方法 |
| CA2942100A1 (en) * | 2014-03-20 | 2015-09-24 | Esperion Therapeutics, Inc. | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders |
| CN104127391B (zh) * | 2014-08-05 | 2016-08-24 | 李宝齐 | 一种含有阿托伐他汀钙的固体药物组合物 |
| MX2018005096A (es) * | 2015-11-06 | 2018-08-15 | Gemphire Therapeutics Inc | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. |
| CN105434391A (zh) * | 2016-01-18 | 2016-03-30 | 上海蓝心医药科技有限公司 | 阿托伐他汀钙肠溶片及其制备方法和应用 |
-
2016
- 2016-11-07 MX MX2018005096A patent/MX2018005096A/es unknown
- 2016-11-07 HK HK19100291.5A patent/HK1257929A1/zh unknown
- 2016-11-07 KR KR1020187013334A patent/KR20180073597A/ko not_active Withdrawn
- 2016-11-07 CA CA3001627A patent/CA3001627A1/en not_active Abandoned
- 2016-11-07 JP JP2018543283A patent/JP2018536710A/ja active Pending
- 2016-11-07 WO PCT/US2016/060837 patent/WO2017079748A1/en not_active Ceased
- 2016-11-07 CN CN201680064715.0A patent/CN108366957A/zh active Pending
- 2016-11-07 KR KR1020187014906A patent/KR20180073665A/ko not_active Withdrawn
- 2016-11-07 CA CA3000016A patent/CA3000016A1/en not_active Abandoned
- 2016-11-07 EP EP16863175.2A patent/EP3370703A4/en not_active Withdrawn
- 2016-11-07 SG SG10201912754UA patent/SG10201912754UA/en unknown
- 2016-11-07 SG SG11201803442UA patent/SG11201803442UA/en unknown
- 2016-11-07 AU AU2016349634A patent/AU2016349634A1/en not_active Abandoned
- 2016-11-07 MX MX2018005540A patent/MX2018005540A/es unknown
- 2016-11-07 BR BR112018007857A patent/BR112018007857A2/pt not_active Application Discontinuation
- 2016-11-07 EP EP16863170.3A patent/EP3370713A4/en not_active Withdrawn
- 2016-11-07 BR BR112018009238A patent/BR112018009238A8/pt not_active Application Discontinuation
- 2016-11-07 AU AU2016348638A patent/AU2016348638A1/en not_active Abandoned
- 2016-11-07 CN CN201680064197.2A patent/CN108348491A/zh active Pending
- 2016-11-07 RU RU2018120599A patent/RU2018120599A/ru not_active Application Discontinuation
- 2016-11-07 HK HK19101864.0A patent/HK1259458A1/zh unknown
- 2016-11-07 MA MA043190A patent/MA43190A/fr unknown
- 2016-11-07 JP JP2018543079A patent/JP2018532808A/ja active Pending
- 2016-11-07 RU RU2018120726A patent/RU2018120726A/ru not_active Application Discontinuation
- 2016-11-07 WO PCT/US2016/060849 patent/WO2017079755A1/en not_active Ceased
-
2017
- 2017-01-26 US US15/416,911 patent/US9849104B2/en active Active
- 2017-02-03 US US15/424,620 patent/US20170172955A1/en not_active Abandoned
- 2017-11-16 US US15/814,557 patent/US10449154B2/en active Active
-
2018
- 2018-04-22 IL IL258819A patent/IL258819A/en unknown
- 2018-05-04 PH PH12018500972A patent/PH12018500972A1/en unknown
- 2018-05-04 US US15/971,491 patent/US20180325825A1/en not_active Abandoned
- 2018-05-04 IL IL259133A patent/IL259133A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018120599A (ru) | Лечение смешанной дислипидемии | |
| JP6295205B2 (ja) | 心血管疾患のリスクを低減する方法 | |
| Mani et al. | Niacin therapy, HDL cholesterol, and cardiovascular disease: is the HDL hypothesis defunct? | |
| FI3911648T3 (fi) | 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön | |
| JP2012097105A5 (enExample) | ||
| RU2017136295A (ru) | Фиксированные комбинации и составы, содержащие етс1002 и один или более статинов, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания | |
| EP3035934A2 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| RU2018133690A (ru) | Лечение пациентов с гомозиготной семейной гиперхолестеринемией, получающих липидоснижающую терапию | |
| JP2012505905A5 (enExample) | ||
| JP2017519028A5 (enExample) | ||
| JP2019533705A5 (enExample) | ||
| JP2007527433A5 (enExample) | ||
| US7776354B2 (en) | Remedies for glomerular diseases | |
| JP2020535142A5 (enExample) | ||
| JP2018027953A (ja) | 膵炎を治療するためのゲムカベンおよび誘導体 | |
| KR20230142523A (ko) | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 | |
| JP2014509305A5 (enExample) | ||
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| ES2346969T3 (es) | Uso de inhibidores de trombina de bajo peso molecular en terapia de disminucion de colesterol. | |
| Park et al. | KOREAN ROSUVASTATIN EFFECTIVENESS STUDY IN NONDIABETIC METABOLIC SYNDROME (KREST) | |
| Chapman | Current drug information: Excess cardiovascular risk in inflammatory rheumatic diseases | |
| Paragh et al. | ANIMAL MODEL FOR SIMULTANEOUS STUDY OF STATIN-EFFECTS AGAINST HYPERCHOLESTEROLEMIA AND TUMOR DEVELOPMENT | |
| Chapman | Current drug information: High-dose statin therapy for more effective cardiovascular prevention | |
| Blom et al. | Rosuvastatin reduces non-HDL-cholesterol and lipoprotein remnants in Fredrickson type III hyperlipoproteinaemia patients | |
| RU2022101523A (ru) | Фиксированные комбинации и составы, содержащие etc-1002 и один или более статинов, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания |